Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303039 | 1.00 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27916631 | 0.98 | MAOB (0.62) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL11065204 | 0.89 | MAOB (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL11063012 | 0.89 | MAOB (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL8174415 | 0.86 | MAOB (0.59) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL68886 | 0.85 | RAB9A (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL17361593 | 0.82 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2056164 | 0.81 | MAOB (0.54) | MAOBMAOANPC1CYP19A1 | |
| SCHEMBL4728838 | 0.79 | MAOB (0.66) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| Ethylene Glycol SCHEMBL9338892 | 0.78 | MAOB (0.48) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2022217248-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-112759580-B | Preparation method of chroman-4-one and derivatives thereof | 河南大学 | 2022-05-17 | — | — | CN | disclosed |
| EP-3994125-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-7417057-B2 | Pesticidal heterocycles | BAYER CROPSCIENCE AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1499609-A4 | PESTICIDAL HETEROCYCLES | FMC CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050143418-A1 | Pesticidal heterocycles | FMC CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1499609-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003092374-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | MAOB 38/4885MAOA 85/4885GRM5 261/4885 |
| US-20050143418-A1 | Pesticidal heterocycles | DDT, TRHR, ACHE | MAOB 773/4885MAOA 1080/4885GRM5 3254/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | MAOB 186/4885MAOA 267/4885GRM5 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.